By The ASCO Post StaffPosted: 12/16/2019 9:06:00 AM Last Updated: 12/20/2019 1:45:34 PM When the CXCR4 inhibitor BL-8040 was combined with the programmed cell death protein 1 (PD-1) inhibitor pembrolizumab plus chemotherapy in the second-line setting, the regimen showed promising antitumor…
Patients with active cancer who developed venous thromboembolism (VTE) and were treated with anticoagulants for at least 6 months, followed by an additional 12 months…
Sylvester Researchers study QoL During Immunotherapy Treatment / cancer, Gilberto Lopes, immunotherapy treatment, Jose Lutzky, OncoDaily, Oncology, Patricia
The DCC is a year-round collective community movement to raise money in support of Sylvester Comprehensive Cancer Center at the University of Miami. With your…
The Year in Review in Oncology 2024 brought to you by some of the Worlds TOP experts!
The Year in Review in Oncology 2024 brought to you by some of the Worlds TOP experts!
Recent statistics showing reductions in lung cancer–related mortality may not address trends linked to tobacco use, air pollution, and asbestos exposure.
WEDNESDAY, Jan. 15, 2025 (HealthDay News) — Tobacco-associated trachea, bronchus, and lung (TBL) cancer mortality is declining, while ambient particulate matte
Matteo Lambertin: Exciting to start the ESMO preceptorship on Breast Cancer with Rebecca Dent / breastcancer, cancer, Education, ESMO, European Society,
Chinmay Jani: Presenting collaborative project on HRR testing / cancer, Chinmay Jani, FLASCO, HRR testing guidelines, OncoDaily, Oncology, Pfizer Oncology,
Coral Olazagasti: Head and neck cancer updates at ESMO USA / cancer, Coral Olazagasti, ESMO, head cancer, neck cancer, OncoDaily, Oncology, sylvester Cancer
